Filing Flows

Filing Flows › Companies › Firefly Neuroscience › Cash flow

Firefly Neuroscience cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$1.8M in Q2 2026 · −$7.0M over twelve months

Operating cash flow−$1.8M
Free cash flow−$1.8M
Cash conversion cycle-326 days

Analysis

In Q2 2026, Firefly Neuroscience generated −$1.8M of operating cash flow. That is $640K more than in Q2 2025 (−$2.4M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$7.0M; the largest uses were operating cash flow ($7.0M), other investing ($209K); besides operations, cash came from other financing ($10.5M); the cash balance rose by $3.3M.

Operating cash flow was −$1.8M against net income of −$2.0M. The largest differences: payables −$448K, stock-based pay +$268K, accrued liabilities +$71K.

Its cash conversion cycle was -326 days (receivables 34 + inventory 26 − payables 385): suppliers fund its working capital.

Free cash flow

Firefly Neuroscience: free cash flow by quarterFirefly Neuroscience: free cash flow by quarter−$2.5MQ3 2024−$1.2MQ4 2024−$2.5MQ1 2025−$2.4MQ2 2025−$1.5MQ3 2025−$1.8MQ4 2025−$1.9MQ1 2026−$1.8MQ2 2026
Operating cash flow less capital spending.
Firefly Neuroscience: operating cash flow against capital spendingFirefly Neuroscience: operating cash flow against capital spendingOperating cash flowCapital spending−$2.5M$0Q3 2024−$1.2M$0Q4 2024−$2.5M$0Q1 2025−$2.4M$0Q2 2025−$1.5M$0Q3 2025−$1.8M$0Q4 2025−$1.9M$0Q1 2026−$1.8M$0Q2 2026
Latest (Q2 2026): Operating cash flow −$1.8M, Capital spending $0.

Capital allocation, year by year

Firefly Neuroscience: where the cash came from (up) and went (down), by fiscal yearFirefly Neuroscience: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedAsset salesCapital spendingAcquisitionsFY2021: Operating cash flow −$735KFY2021: Shares issued $13.4MFY2021: Capital spending −$70K$13.4MFY2021FY2022: Operating cash flow −$6.0MFY2022: Net borrowing $425KFY2022: Shares issued $1.9MFY2022: Capital spending −$536K$2.3MFY2022FY2023: Operating cash flow −$2.2MFY2023: Net borrowing $75KFY2023: Shares issued $355KFY2023: Asset sales $936K$1.4MFY2023FY2024: Operating cash flow −$6.2MFY2024: Net borrowing $2.0MFY2024: Acquisitions −$62K$2.0MFY2024FY2025: Operating cash flow −$8.2MFY2025: Net borrowing $2.5M$2.5MFY2025
Over these 5 years operating cash flow totalled −$23.3M; the largest uses were operating cash flow ($23.3M) and capital spending ($606K). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$9.2M
Debtnone
Net cash$9.2M
Cash runway16 months

Firefly Neuroscience is burning cash: its operations consume cash, a free cash flow of −$7.0M a year at the current rate against $9.2M of cash and investments: a runway of about 16 months before any new financing.

Where the cash came from and went

Firefly Neuroscience: sources (+) and uses (−) of cash, Q2 2026Firefly Neuroscience: sources (+) and uses (−) of cash, Q2 2026Other financing$7.9MCash drawn (+) / kept (−)−$6.1MOperating cash flow−$1.8MOther investing−$42K
Firefly Neuroscience: sources (+) and uses (−) of cash, TTM to Q2 2026Firefly Neuroscience: sources (+) and uses (−) of cash, TTM to Q2 2026Other financing$10.5MOperating cash flow−$7.0MCash drawn (+) / kept (−)−$3.3MOther investing−$209K

From profit to cash

Firefly Neuroscience: net income to operating cash flow, Q2 2026Firefly Neuroscience: net income to operating cash flow, Q2 2026Net income−$2.0MDepreciation & amortization$47KStock-based pay$268KReceivables$5KInventory$59KPayables−$448KAccrued liabilities$71KDeferred revenue$14KPrepaid and other assets−$56KOperating cash flow−$1.8M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q2 20263426385-326
Q1 20263636456-384
Q3 20254540541-456

Every quarter

QuarterOperating cash flowCash drawn (+) / kept (−)Free cash flow
Q2 2026−$1.8M−$6.1M−$1.8M
Q1 2026−$1.9M−$380K−$1.9M
Q4 2025−$1.8M$1.6M−$1.8M
Q3 2025−$1.5M$1.6M−$1.5M
Q2 2025−$2.4M$3.6M−$2.4M
Q1 2025−$2.5M−$7.7M−$2.5M
Q4 2024−$1.2M−$580K−$1.2M
Q3 2024−$2.5M−$872K−$2.5M

Firefly Neuroscience: income statement and cash flow

Firefly Neuroscience, Q2 2026: revenue $514K (+72% year over year), operating margin -384.0%. The chart follows the revenue to costs, profit and cash.

Firefly Neuroscience: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.